Development of OPN-305 as an orphan drug for the treatment of Delayed Graft Function post solid organ transplantation
Public support
Provider
Ministry of Education, Youth and Sports
Programme
—
Call for proposals
FP7-HEALTH-2010-single-stage
Main participants
—
Contest type
RP - Co-financing of EC programme
Contract ID
34668/2012-32
Alternative language
Project name in Czech
Development of OPN-305 as an orphan drug for the treatment of Delayed Graft Function post solid organ transplantation
Annotation in Czech
Delayed graft function (DGF) is defined as the need for dialysis within seven days of renal transplantation (DGF promotes allograft rejection, requires prolonged dialysis and hospitalisation, and increases the likelihood of graft failure and ultimately the duration of renal graft survival-expectancy. The incidence of DGF occurs in 21-44% of cases following cadaveric renal graft. Several rare diseases, particularly those of genetic origin, are associated with the requirement for solid organ transplantation as the disease progresses. At Opsona Therapeutics we have developed a novel antibody (OPN305) which has received OMP designation (EU/3/09/638) for use in the prevention of DGF. The scientific basis of this development is the inhibition of Toll-like receptor 2 (TLR2)-mediated ischaemic reperfusion injury which has a pivotal role in the pathogenesis of DGF and its sequelae. The MABSOT project is designed to progress the development of this OMP through Phase I and IIa clinical trial. The successful completion of the programme will allow the continued development of OPN305 as an OMP for the treatment of DGF in a range of solid organ transplant situations. OPN305 development will have significant benefit to these patients and health care providers in reducing the prolonged hospitalisation of these individuals, providing greater longevity associated with the transplanted organ and enhanced quality of life for these individuals.
Scientific branches
R&D category
AP - Applied research
CEP classification - main branch
FJ - Surgery including transplantology
CEP - secondary branch
FJ - Surgery including transplantology
CEP - another secondary branch
FJ - Surgery including transplantology
OECD FORD - equivalent branches <br>(according to the <a href="http://www.vyzkum.cz/storage/att/E6EF7938F0E854BAE520AC119FB22E8D/Prevodnik_oboru_Frascati.pdf">converter</a>)
30212 - Surgery<br>30213 - Transplantation
Completed project evaluation
Provider evaluation
U - Uspěl podle zadání (s publikovanými či patentovanými výsledky atd.)
Project results evaluation
Following the condition that the candidate of financial contribution was evaluated and afterwards selected by international provider in accordance with the rules of the program the Ministry of Education, Youth ans Sports does not realize the evaluation of project results. The project is evaluated only after its approval by an international provider.
Solution timeline
Realization period - beginning
Jan 1, 2012
Realization period - end
Nov 30, 2013
Project status
U - Finished project
Latest support payment
Mar 20, 2013
Data delivery to CEP
Confidentiality
C - Předmět řešení projektu podléhá obchodnímu tajemství (§ 504 Občanského zákoníku), ale název projektu, cíle projektu a u ukončeného nebo zastaveného projektu zhodnocení výsledku řešení projektu (údaje P03, P04, P15, P19, P29, PN8) dodané do CEP, jsou upraveny tak, aby byly zveřejnitelné.
Data delivery code
CEP14-MSM-7E-U/01:1
Data delivery date
Jun 30, 2014
Finance
Total approved costs
2,786 thou. CZK
Public financial support
2,786 thou. CZK
Other public sources
0 thou. CZK
Non public and foreign sources
0 thou. CZK